Quick Answer
Black Diamond Therapeutics, Inc. reported Research And Development Expense of $33.56 million for the year ending 2025.
- Black Diamond Therapeutics, Inc. showed a decrease of -34.6% in Research And Development Expense from 2024 to 2025.
- This data is from Black Diamond Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 8 years of available data (2018 to 2025), Black Diamond Therapeutics, Inc.'s Research And Development Expense has grown by 382.8%.
- Historical annual values: Fiscal year 2025: $33.56 million | Fiscal year 2024: $51.31 million | Fiscal year 2023: $59.35 million | Fiscal year 2022: $64.44 million | Fiscal year 2021: $96.83 million | Fiscal year 2020: $48.21 million | Fiscal year 2019: $21.75 million | Fiscal year 2018: $6.95 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: